Nasal Decongestant Spray: Usage Limit & Risks Revealed

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has updated its guidance on over-the-counter nasal decongestant sprays, limiting the recommended duration of use to five days. This change, announced on April 30, 2026, aims to mitigate the risk of rebound congestion, a condition where prolonged use leads to worsening congestion and dependence on the spray.

The MHRA’s decision follows growing awareness of the potential for overuse and its associated negative effects. While these sprays provide temporary relief from stuffiness caused by colds, allergies, and sinusitis, exceeding the recommended five-day limit can create a cycle of reliance, according to the regulator.

Rebound Congestion: The Risk of Prolonged Use

Rebound congestion, also known as rhinitis medicamentosa, occurs when the blood vessels in the nasal passages become accustomed to the constricting effects of the decongestant. When the medication wears off, these vessels swell, leading to increased congestion and a perceived need to use the spray again. This can create a vicious cycle, making the initial congestion worse and hindering the natural healing process.

The updated guidance applies to nasal sprays containing ingredients like xylometazoline and oxymetazoline, commonly found in many over-the-counter decongestant products. Consumers are now advised to consult a healthcare professional if congestion persists beyond five days.

Industry Response and Consumer Awareness

While the MHRA has not yet issued specific directives to manufacturers regarding packaging changes, the move signals a need for clearer labeling and increased consumer education. The regulator’s announcement underscores the importance of reading and adhering to the instructions provided with these medications.

The change in guidance comes amid broader discussions about the appropriate use of over-the-counter medications and the potential for unintended consequences. Health officials are increasingly focused on empowering consumers with the information they need to make informed decisions about their health.

Business Implications for Pharmaceutical Companies

The revised guidance could have implications for pharmaceutical companies that manufacture and market nasal decongestant sprays. While the products remain available for short-term use, the reduced recommended duration may impact sales volumes. Companies may need to invest in consumer education campaigns to promote responsible use and mitigate potential declines in revenue.

the MHRA’s action could prompt a review of similar regulations in other countries, potentially leading to a global shift in the recommended use of these medications. Pharmaceutical companies will need to monitor these developments closely and adapt their strategies accordingly.

The MHRA’s announcement is likely to spur increased scrutiny of other over-the-counter medications with potential for overuse or dependence. This could lead to further regulatory changes and a greater emphasis on patient safety and responsible self-medication.

The regulator’s decision reflects a growing trend towards more cautious and evidence-based approaches to healthcare regulation. By prioritizing patient safety and addressing the risks associated with prolonged medication use, the MHRA aims to ensure that consumers can benefit from these products without experiencing unintended harm.